3.4
3.5 
3.3 
3.9 
4.1 3.0
3.1 3.6 3.4 3.4 VISIT:
FIRM OVERVIEW: Large Private VC founded in 1973 based out of London, UK (Europe)
FIRM DESCRIPTION: In January 2007, Abingworth, the international life sciences investment group, announced the final closing of its £300 million ($587 million) life sciences fund, Abingworth Bioventures V LP (ABV V). This is Abingworth’s 8th life sciences fund and the largest venture fund dedicated to life sciences raised by a firm based in Europe. ABV V will invest in biotechnology and medical companies, both in Europe and the US. The fund will invest broadly across the life sciences field in technologies, therapeutics and medical devices at all stages of development from early-stage private deals to quoted companies. Investment size will generally range from £7.5 million up to £20 million per investment after all private rounds of financing. It is planned to make more than 20 venture investments.
TEAM MEMBERS: Jonathan MacQuitty, Michael Bigham, Stephen Bunting,
FUND NEWS: More / RSS by Orglex
Very smart group; extensive contacts in the UK and Europe; willingness to invest in early-stage companies/technologies (in the life science space); highly recommend them
PRIVATE: Members Only (51 Characters)